Literature DB >> 17934385

Balancing efficacy and safety in treatment with antipsychotics.

Christoph U Correll1.   

Abstract

Balancing efficacy with tolerability and safety of prescribed treatments is critical to optimizing antipsychotic treatment outcomes in the mentally ill. Symptom control, symptom remission, and functional recovery are only realistic goals when treatments are both effective and well tolerated. The consideration of predictable differences in antipsychotic adverse-effect profiles is central to successful illness management. Minimizing adverse effects on alertness, motivation, cognition, sexual/reproductive functioning, and physical health enhances mental health outcomes, partly through improving treatment adherence. Neuroendocrine and metabolic side effects of antipsychotics for cardiovascular morbidity and mortality need to be addressed proactively and aggressively. In view of the widespread lack of primary care engagement and the adverse effects of psychotropic medications on cardiovascular health, psychiatric care providers should function as key facilitators of an integrated mental and physical health management approach. In addition to psychoeducation and healthy lifestyle counseling, clinicians can improve psychiatric and physical health by selecting medications carefully, routinely screening and monitoring for reversible cardiovascular risk factors, and playing an active role in the prevention and interdisciplinary management of cardiovascular risk factors and medical illness in the vulnerable mentally ill.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934385     DOI: 10.1017/s1092852900026298

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  17 in total

1.  Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study.

Authors:  Jian-Ping Zhang; Jeffrey J Weiss; Melissa McCardle; Hope Klopchin; Eileen Rosendahl; Lawrence Maayan; Antonio Convit; John M Kane; Peter Manu; Christoph U Correll
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

Review 2.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

3.  Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

Authors:  Britta Galling; Alexandra Roldán; Katsuhiko Hagi; Liz Rietschel; Frozan Walyzada; Wei Zheng; Xiao-Lan Cao; Yu-Tao Xiang; Mathias Zink; John M Kane; Jimmi Nielsen; Stefan Leucht; Christoph U Correll
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

4.  The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology.

Authors:  Marc De Hert; Mauro Mauri; Ken Shaw; Tilman Wetterling; Adam Doble; Agnès Giudicelli; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2010-12       Impact factor: 4.035

Review 5.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

6.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 7.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

8.  Sex difference in the association of body mass index and BDNF levels in Chinese patients with chronic schizophrenia.

Authors:  Fang Yang; Keming Wang; Xiangdong Du; Huiqiong Deng; Hanjing Emily Wu; Guangzhong Yin; Yuping Ning; Xingbing Huang; Antonio L Teixeira; João de Quevedo; Jair C Soares; Xiaosi Li; XiaoE Lang; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-11-19       Impact factor: 4.530

9.  Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

Authors:  Jonathan M Meyer; Vicki G Davis; Joseph P McEvoy; Donald C Goff; Henry A Nasrallah; Sonia M Davis; Gail L Daumit; John Hsiao; Marvin S Swartz; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2008-06-04       Impact factor: 4.939

Review 10.  Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.

Authors:  Alex J Mitchell; Davy Vancampfort; Amber De Herdt; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.